Evidence map›Paper›PMID 40614866›Full record

ReviewAdvanced drug delivery reviews2025

The intersection of circadian rhythms and the blood-brain barrier with drug efficacy and delivery in neurological disorders.

Kyra A Schindler, Silvia Torices, Nicolette Schurhoff, Daniela Iglesias Gallo, Michal Toborek

Abstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kyra A SchindlerUniversity of Miami Miller School of Medicine, Department of Biochemistry and Molecular Biology, Miami, FL, USA; University of Miami Miller School of Medicine, Medical Scientist Training Program, Miami, FL, USA. Electronic address: kas460@med.miami.edu.
Silvia ToricesUniversity of Miami Miller School of Medicine, Department of Biochemistry and Molecular Biology, Miami, FL, USA.
Nicolette SchurhoffUniversity of Miami Miller School of Medicine, Department of Biochemistry and Molecular Biology, Miami, FL, USA.
Daniela Iglesias GalloUniversity of Miami Miller School of Medicine, Department of Biochemistry and Molecular Biology, Miami, FL, USA.
Michal ToborekUniversity of Miami Miller School of Medicine, Department of Biochemistry and Molecular Biology, Miami, FL, USA; Institute of Physiotherapy and Health Sciences, the Blood-Brain Barrier Research Center, the Jerzy Kukuczka Academy of Physical Education, Katowice, Poland. Electronic address: mtoborek@med.miami.edu.

Funding

Tat, amyloid beta and brain endothelial barrier functionR01MH072567 · NIMH · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Michal Toborek · 2005 to 2026
$7.6M
Medical Scientist Training ProgramT32GM145462 · NIGMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ALESSIA FORNONI, Daniel Jon Liebl · 2022 to 2026
$3.9M
Role of cerebral vasculature in brain ischemia in HIV infectionR01HL126559 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TOBOREK, MICHAL · 2014 to 2024
$3.8M
Targeting Inflammasomes in Substance Abuse and HIVR01DA050528 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TOBOREK, MICHAL · 2020 to 2024
$2.3M
Defining brain pericytes as a novel and myeloid-derived HIV reservoirR01MH128022 · NIMH · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TOBOREK, MICHAL · 2021 to 2025
$2.3M
Prevention of HIV and drug abuse-induced brain pathology by targeting mitochondriaR01DA044579 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TOBOREK, MICHAL · 2017 to 2021
$2.2M
Inflammasome Activation and Gut-Brain Axis Dysregulation in HIV and Methamphetamine-Associated DepressionR01DA059849 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Eleonore Beurel, Michal Toborek · 2024 to 2026
$1.7M
Adolescent exposure to PCBs as a risk factor for the development of depressionR01ES036983 · NIEHS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Eleonore Beurel, Michal Toborek · 2025 to 2026
$996k
Novel role of inflammasome activation in ART neurotoxicityR21MH122235 · NIMH · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TOBOREK, MICHAL · 2020 to 2021
$422k
CCL2/CCR2 modulates HIV-associated ischemic stroke by regulating blood brain barrier monocyte recruitmentR21NS141704 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TORICES, SILVIA · 2024 to 2024
$422k
NHLBI NIH HHS R01 HL126559NIDA NIH HHS R01 DA044579NIDA NIH HHS R01 DA050528NIDA NIH HHS R01 DA059849NIEHS NIH HHS R01 ES036983NIGMS NIH HHS T32 GM145462NIMH NIH HHS R01 MH072567NIMH NIH HHS R01 MH128022NIMH NIH HHS R21 MH122235NINDS NIH HHS R21 NS141704
6 · The paper itself

Abstract

Circadian rhythms typically maintain a 24-hour cycle which determines the regulation of many genes and proteins including, but not limited to, those which control the permeability of the blood brain barrier (BBB). The BBB acts as a boundary between circulating blood and the brain, protecting the brain from toxicants, maintaining homeostasis, and regulating perfusion. Importantly, the BBB regulates the efficacy of drug delivery into the central nervous system (CNS). Emerging evidence demonstrates a bi-directional relationship between circadian rhythm dysfunction, neurological disorders, and/or BBB disruption. This means that impaired BBB functions and circadian rhythm dysregulation can be both the driver of neurological disease and the result. As such, both represent an opportunity for therapeutic intervention which can prevent disease development, manage symptoms, or mediate disease progression. This review seeks to describe the changes in both the BBB and circadian rhythms in a series of neurological (stroke, epilepsy, traumatic brain injury), neurodegenerative (Alzheimer's disease, Parkinson's disease), and psychiatric disorders (major depressive disorder, schizophrenia). We also describe therapeutic approaches for protecting against both BBB and circadian rhythm dysfunction, methods of surpassing the BBB, and bolstering drug efficacy with chronotherapeutic strategies.

Indexed as

Blood-Brain BarrierCircadian RhythmDrug Delivery SystemsNervous System DiseasesAnimalsHumansBlood–brain barrierChronotherapyCircadian rhythmDrug deliveryNeurodegenerative disordersNeurological disordersPsychiatric disorders

Identifiers

PMID40614866
PMCPMC12321092

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.